Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMIG4.L Regulatory News (MIG4)

  • There is currently no data for MIG4

Interim Management Statement

14 Nov 2022 16:00

RNS Number : 3503G
Mobeus Income & Growth 4 VCT PLC
14 November 2022
 

 

Mobeus Income & Growth 4 VCT plc

("the Company")

LEI: 213800IFNJ65R8AQW943

 

INTERIM MANAGEMENT STATEMENT

For the quarter ended 30 September 2022

 

Mobeus Income & Growth 4 VCT plc presents an Interim Management Statement for the quarter ended 30 September 2022. The statement also includes relevant financial information between the end of the period and the date of this statement.

 

NET ASSET VALUE AND TOTAL RETURN PER SHARE

At 30 September 2022

(unaudited)

At 30 June 2022

(unaudited)

Net assets attributable to shareholders

£78.93 million

£86.13 million

Shares in issue

91,244,441

90,990,361

Net asset value (NAV) per share

86.50 pence

94.66 pence

Cumulative dividends paid

147.20 pence

143.20 pence

Cumulative Total return (net asset value basis) per share since inception

233.70 pence

237.86 pence

 

The NAV per share has decreased by 8.16 pence in the quarter (a decrease of 8.6% from the opening NAV per share). This decrease arises both from the 4.00 pence per share dividend paid in July 2022 as well as a fall in unrealised valuations. On a total return basis, after adding back the dividend of 4.00 pence per share, the decrease is 4.4%.

 

OFFER FOR SUBSCRIPTION

 

On 17 October 2022, the Company took part in a Joint Offer for Subscription ("Offer") alongside the other Mobeus VCTs seeking to raise an initial amount of £11 million for the Company with an over-allotment facility of £5 million available. Following strong demand for the Offer, the Directors approved the utilisation of the over-allotment facility later on 17 October 2022. As stated in the Prospectus, the first allotment under the Offer in relation to applications accepted for the initial amount is expected on or around 16 November 2022. Accepted applications by the Company for the over-allotment facility will be allotted in January 2023.

 

DIVIDENDS PAID/DECLARED IN THE PERIOD

 

On 8 July 2022, an interim dividend of 4.00 pence per share in respect of the year ending 31 December 2022 was paid to all Shareholders whose names were on the register on 27 May 2022.

 

A second interim dividend of 6.00 pence per share in respect of the year ending 31 December 2022 was declared on 13 September 2022. This was paid on 7 November 2022 to those Shareholders on the Register of Members on 23 September 2022. Payment of this second interim dividend has reduced NAV per share (shown above) to 80.50 pence and increased cumulative dividends paid to 153.20 pence per share. 

 

DIVIDEND INVESTMENT SCHEME ("DIS")

 

On 8 July 2022, 586,156 shares were allotted through the DIS during the period at a price of 98.69 pence per share.

 

INVESTMENT ACTIVITY DURING THE PERIOD

 

New Investment during the period

On 9 September 2022, the Company completed a new investment of £0.50 million into Focalpoint Positioning Limited, a navigation and positioning technology company.

 

On 12 September 2022, a new investment of £0.44 million was made into Orri Limited, a provider of specialist eating disorder treatments.

 

Follow-on investments during the period

On 5 July 2022, a follow on investment of £0.62 million was made into Vivacity Labs Limited, an AI and urban traffic control business.

 

On 23 August 2022, a follow on investment of £0.33 million was made into Bleach London Holdings Limited, a hair colourants brand.

 

Loan repayments and other proceeds during the period

The Company received deferred consideration of £0.04 million from Media Business Insight Holdings Limited, an investment realised in a prior quarter.

 

Share buy-backs

On 23 September 2022, the Company purchased 332,076 of its own ordinary shares at a price of 80.43 pence per share.

 

All shares bought back by the Company were subsequently cancelled.

 

ACTIVITY AFTER THE PERIOD END

 

Loan Repayments and other proceeds

On 21 October 2022, a loan repayment (including premium) from Jablite Holdings Limited of £0.05 million was received.

 

Share buy-backs

On 7 October 2022, the Company purchased 338,012 of its own ordinary shares at a price of 80.43 pence per share.

 

All shares bought back by the Company were subsequently cancelled.

 

 

DIVIDEND INVESTMENT SCHEME ("DIS")

On 7 November 2022, 1,129,699 shares were allotted through the DIS at a price of 80.50 pence per share.

 

 

 

Please note that all of the above information is unaudited.

 

Other than as described above, there were no material events during the period and to the date of this announcement.

 

For further information, please contact:

Gresham House Asset Management Limited

Company Secretary: 020 7382 0999

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEZLFFLFLLFBK
Date   Source Headline
26th Mar 201912:33 pmRNSAnnual Financial Report
20th Mar 20194:07 pmRNSAnnual Results for the year ended 31 December 2018
20th Dec 201810:13 amRNSTransaction in Own Shares
26th Nov 20189:23 amRNSTransaction in Own Shares
16th Nov 20189:55 amRNSInterim Management Statement - 3rd Quarter Results
27th Sep 201811:11 amRNSTransaction in Own Shares
15th Aug 20185:09 pmRNSSubmission to the NSM
14th Aug 201811:37 amRNSDividend Investment Scheme - Suspension
14th Aug 201811:15 amRNSDividend Investment Scheme - Suspension
14th Aug 201810:39 amRNSHalf-year Report
20th Jun 201810:31 amRNSIssue of Equity
6th Jun 20189:33 amRNSTransaction in Own Shares
11th May 20182:34 pmRNSInterim Management Statement
11th May 20182:30 pmRNSResult of AGM
11th May 20182:26 pmRNSDividend Declaration
26th Mar 20188:50 amRNSTransaction in Own Shares
22nd Mar 20182:37 pmRNSAnnual Financial Report
20th Mar 20185:39 pmRNSAnnual Financial Report
13th Mar 20184:33 pmRNSIssue of Equity
25th Jan 201812:02 pmRNSIssue of Equity
5th Jan 201812:40 pmRNSRealisation of Investment in Gro-Group
5th Jan 201811:23 amRNSTotal Voting Rights
21st Dec 20174:33 pmRNSIssue of Equity
21st Dec 201711:49 amRNSTransaction in Own Shares
20th Dec 20171:57 pmRNSPublication of Suppl.Prospcts
30th Nov 20179:15 amRNSJoint Announcement - Fundraising Update
30th Nov 20179:15 amRNSJoint Announcement - Fundraising Update
30th Nov 20179:14 amRNSJoint Announcement - Fundraising Update
30th Nov 20179:11 amRNSJoint Announcement - Fundraising Update
22nd Nov 20179:30 amRNSIssue of Equity
21st Nov 20175:12 pmRNSDividend Declaration
21st Nov 201710:02 amRNSIssue of Equity
16th Nov 20172:01 pmRNSInterim Management Statement
10th Nov 201710:27 amRNSIssue of Equity
1st Nov 201712:44 pmRNSIncrease in Offer size. Expiry of early incentive.
20th Oct 20172:24 pmRNSDirector/PDMR Shareholding
20th Oct 20172:22 pmRNSIssue of Equity
13th Oct 20172:48 pmRNSDecision to utilise over-allotment facility
29th Sep 201710:24 amRNSDirector/PDMR Shareholding - Replacement
29th Sep 20179:18 amRNSDirector/PDMR Shareholding
29th Sep 20179:17 amRNSIssue of Equity
18th Sep 20179:09 amRNSTransaction in Own Shares
11th Sep 20174:35 pmRNSIssue of Equity
6th Sep 20174:35 pmRNSOffer for Subscription and Issue of Prospectus
6th Sep 20174:35 pmRNSOffer for Subscription and Issue of Prospectus
6th Sep 20174:34 pmRNSOffer for Subscription and Issue of Prospectus
6th Sep 20174:34 pmRNSOffer for Subscription and Issue of Prospectus
8th Aug 20175:34 pmRNSHalf-year Report
8th Aug 20173:53 pmRNSHalf-year Report
4th Aug 20175:10 pmRNSJoint Announcement - Fundraising Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.